Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

THG Q2 trading 'much improved' across both divisions

(Sharecast News) - Online retailer THG said on Tuesday that Q2 trading has been "much improved" across both its beauty and nutrition units, with the overall group returning to constant currency revenue growth, underpinned by a "strong June exit rate". Following "a significant improvement" quarter-on-quarter, THG said its beauty arm was expected to deliver a revenue decline of between 2.0% and 3.0%, up from Q1's 9.8% drop. Beauty retail, which comprises the vast majority of the THG beauty business, "traded resiliently", with growth in the UK at its highest rate since Q124, supporting market share gains

The FTSE 250-listed firm also noted that "positive momentum" within its nutrition division continued to build, with revenue growth expected to be between 5.0% and 7.0% in Q2, up from the 0.1% uptick seen in Q1 and the business' fastest growth rate since Q1 2022.

THG added that whilst its direct exposure to tariffs was expected to be less than £1.0m pre-mitigating actions, it was continuing to monitor changes to US trade policy and "reciprocal actions" for an adverse impact on raw material supply chains and US consumer sentiment.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.